Literature DB >> 11304060

Markers of enteric inflammation in enteroaggregative Escherichia coli diarrhea in travelers.

A R Bouckenooghe1, H L Dupont, Z D Jiang, J Adachi, J J Mathewson, M P Verenkar, S Rodrigues, R Steffen.   

Abstract

As part of a traveler's diarrhea study carried out in Guadalajara, Mexico, and Goa, India, we conducted a case control study to evaluate fecal markers of enteric inflammation in three groups. Forty-five cases of enteroaggregative Escherichia coli (EAEC) diarrhea were compared to 56 controls with enterotoxigenic E. coli (ETEC) diarrhea, and 126 controls with diarrhea without identifiable pathogens. For EAEC cases we found fecal leukocytes, occult blood, and lactoferrin in 13 (28.9%), 14 (31.1%), and 27 (60.0%) patients, respectively; for ETEC controls they were 15 (26.8%), 16 (28.6%), and 15 (26.8%) respectively; and for patients without identifiable pathogens 19 (15.1%), 34 (27.0%) and 27 (21.4%) were seen for the presence of a positive fecal lactoferrin test in EAEC cases was statistically significant compared to both control groups. The study provides evidence that EAEC infection is associated with an intestinal inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11304060     DOI: 10.4269/ajtmh.2000.62.711

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  Usefulness of fecal lactoferrin in predicting and monitoring the clinical severity of infectious diarrhea.

Authors:  Chien-Chang Chen; Chee-Jen Chang; Tzou-Yien Lin; Ming-Wei Lai; Hsun-Chin Chao; Man-Shan Kong
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Enteroaggregative Escherichia coli: An Emerging Pathogen.

Authors:  David B. Huang; Hoonmo Koo; Herbert L. DuPont
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

3.  Performance assessment of the fecal leukocyte test for inpatients.

Authors:  L A Granville; P Cernoch; G A Land; J R Davis
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

4.  Enteroaggregative Escherichia coli promotes transepithelial migration of neutrophils through a conserved 12-lipoxygenase pathway.

Authors:  Erik J Boll; Carsten Struve; Anja Sander; Zachary Demma; Karen A Krogfelt; Beth A McCormick
Journal:  Cell Microbiol       Date:  2011-10-27       Impact factor: 3.715

5.  Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers.

Authors:  Zhi-Dong Jiang; David Greenberg; James P Nataro; Robert Steffen; Herbert L DuPont
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 6.  Animal models of enteroaggregative Escherichia coli infection.

Authors:  Casandra W Philipson; Josep Bassaganya-Riera; Raquel Hontecillas
Journal:  Gut Microbes       Date:  2013-05-02

7.  Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition.

Authors:  Japheth A Opintan; Mercy J Newman; Patrick F Ayeh-Kumi; Raymond Affrim; Rosina Gepi-Attee; Jesus E A D Sevilleja; James K Roche; James P Nataro; Cirle A Warren; Richard L Guerrant
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

8.  Identification and molecular characterization of EatA, an autotransporter protein of enterotoxigenic Escherichia coli.

Authors:  Seema K Patel; Jimmie Dotson; Kenneth P Allen; James M Fleckenstein
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Travelers' diarrhea: an update on susceptibility, prevention, and treatment.

Authors:  Miguel M Cabada; A Clinton White
Journal:  Curr Gastroenterol Rep       Date:  2008-10

10.  A set of novel multiplex Taqman real-time PCRs for the detection of diarrhoeagenic Escherichia coli and its use in determining the prevalence of EPEC and EAEC in a university hospital.

Authors:  Christoph Hardegen; Sabine Messler; Birgit Henrich; Klaus Pfeffer; Jens Würthner; Colin R MacKenzie
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-22       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.